Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus

Completed · Phase 2

Conditions studied: Skin Infection

In brief

Primary Objective: To make a preliminary assessment of the efficacy of CG400549 (960 mg daily) in subjects with cABSSSI (major cutaneous abscesses) due to MRSA. Secondary Objective(s): * To assess the pharmacokinetics of CG400549 (960 mg daily) in subjects with cABSSSI due to MRSA * To explore the in vitro susceptibility of cABSSSI-related bacteria to CG400549. * To assess the safety of multiple doses of CG400459

Key facts

Study ID

NCT01593761

Run by

CrystalGenomics, Inc.

People needed

20

Starts

2012-06-01

Expected to finish

2012-10-01

Last updated by the study team

2022-09-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of major cutaneous abscess suspected or confirmed to be caused by a MRSA.
• Signs and symptoms should include at least 2 of the following: purulent drainage or discharge, erythema, fluctuance, heat or localized warmth, edema/induration, pain or tenderness to palpation

You may not qualify if…

• Prior systemic or topical antibacterial therapy
• Severe sepsis or refractory shock

Where it is running

• eStudysite — La Mesa, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.